Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Elio Novembre1, Mariangela Tosca2, Carlo Caffarelli3*, Mauro Calvani4, Fabio Cardinale5, Riccardo Castagnoli6,7, Elena Chiappini8, Claudio Cravidi9, Michele Miraglia Del Giudice10, Marzia Duse11, Amelia Licari6,7, Sara Manti12, Alberto Martelli13, Giampaolo Ricci14, Giuseppe Pingitore15 and Gian Luigi Marseglia6,7

Abstract

BNT162b2 vaccine, developed by BioNTech and Pfizer, has recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct allergic evaluation allows identifying patients at risk of developing an anaphylactic reaction. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions.

Keywords: COVID-19, SARS-CoV-2, Vaccine, Children, Adverse event, Allergy, Side effect, mRNA vaccine, Pfizer BioNTech, BNT162b2

Introduction

The Committee for Medicinal Products for Human Use of the European Medicines Agency [1] and AIFA (Italian Medicines Agency) have recently approved the extension of the indication to the BNT162b2 vaccine, developed by BioNTech and Pfizer, for use in children aged 5 to 11 years [2]. The Italian Ministry of Health (Circular 56,429, 7 December 2021) has recently confirmed this extended indication. The BNT162b2 vaccine dose is lower than that used in people 12 years of age and older (10 μg vs. 30 μg). As in the older age group, it is administered intramuscularly in the upper arm and repeated 3 weeks later. The vaccination for children 5–11 years-old is less concentrated and contains excipients such as polyethylene glycol (PEG) and trometamol, but not polysorbates. Therefore, an allergic reaction could occur for one of these excipients, although allergic reactions to trometamol are exceptionally reported [3]. Clinical data on the BNT162b2 vaccine in children aged 5 to 11 years are reported by Centers for Disease Control and Prevention [4]. The most common side effects in this age group are similar to those observed in people aged 12 and over. These data show evidence of safety on the administration of BNT162b2 vaccine in children aged 5 to 11 years and serious adverse events (mainly myocarditis) have been rarely reported. However, parents and guardians of children aged 5 to 11 years should be advised...
that after BNT162b2 vaccine, local and, rarely, systemic reactions could occur, more often after the second dose. A drug/vaccine allergy history is not a contraindication for the BNT162b2 vaccination unless the offending product contains the same excipients. An IgE-dependent allergy is due to antibody recognition of a chemical structure. In this context, a correct evaluation of the allergic response allows identifying patients at real risk of developing an anaphylactic reaction in case of further exposure. Several international public health agencies and allergy organizations worldwide have published guidance related to the concerns for possible severe allergic reactions, specifically to the mRNA vaccine excipients. All reports suggest, in suspected cases, to refer to an allergist for assessment [5–14].

**Risk stratification in allergic and asthmatic children**

On the basis of international documents [5–14], recommendations for adolescents 12–18 years-old of the Italian Society of Pediatric Allergy and Immunology (SIAIP) [15], Italian documents from the Italian Society of Allergy and Clinical Immunology (SIAIC), the Association of Italian Territorial Hospital Allergists (AAITO) [16], and the Italian Ministry of Health [17], three “risk zones” of possible allergic reactions could be identified (Table 1)

1) **Low risk (Green zone)**

This zone includes patients with allergic rhinoconjunctivitis, well-controlled asthma, and non-anaphylactic allergic reactions to foods, insects, and latex.

Action: Proceed with vaccination as usual (as in non-allergic subjects), according to local guidelines. In children treated with allergen immunotherapy, COVID-19 vaccines should be administered at the

| Table 1 | Allergic risk assessment for COVID-19 vaccination in children |
|---------|-------------------------------------------------------------|
| **Low risk** | **Patient characteristics** | **Action** |
| | Allergic rhinoconjunctivitis and allergic well-controlled asthma | Proceed with vaccinations as usual, according to local guidelines. |
| | Non-anaphylactic allergic reactions to food, insects, and latex | |
| | | No allergic evaluation is needed. |
| | Therapies for allergies and/or asthma must be continued as usual. |
| | Children treated with allergen immunotherapy (AIT) should withhold administration for few days (see text). |
| **Medium risk** | **Patient characteristics** | **Action** |
| | Anaphylactic allergic reactions to food, insects, and latex | Consider referral (or teleconsulting) to an allergist-immunologist to confirm the diagnosis and give proper indications. |
| | Idiopathic anaphylaxis and exercise-induced anaphylaxis | Reach the best possible asthma control and then proceed to vaccination. If asthma control is suboptimal, proceed to vaccination in a hospital setting with an observation of at least 60 minutes. |
| | Uncontrolled asthma | Routine vaccination in an outpatient setting with emergency awareness and emergency mediation available. |
| | Mastocytosis | Pre-medication with H1 antihistamine should be considered. |
| | Large local reaction to previous COVID-19 vaccination | For high-risk population (previous anaphylaxis, also to vaccinations, known or suspected allergy to excipients, systemic mastocytosis) see red zone. |
| | Immediate systemic allergic reactions to drugs or vaccines | Specific risk assessment (or teleconsulting) to exclude a possible allergy to PEG or another excipient. |
| | | Routine vaccination in an outpatient setting with emergency awareness and emergency medication available. |
| | | Pre-medication with H1 antihistamine should be considered. |
| | | If skin tests are negative, vaccine should be performed in a hospital setting with an observation of at least 60 minutes. |
| | | If skin tests are positive, see the red zone. |
| **High risk** | **Patient characteristics** | **Action** |
| | - Positive skin tests to excipients | According to allergic risk assessment, the patient may be considered ineligible for a further vaccination or eligible for another vaccination, containing another excipient that resulted negative to the skin test. In all these cases, vaccination must be carried out under strict control in a hospital setting where emergency medical procedures for resuscitation are available. |
| | - Previous allergic reaction to COVID-19 vaccine | |
| | - Previous severe allergic reaction to a component of the vaccine or drugs, including PEG or trometamol | |
interval of 7 days from subcutaneous immunotherapy. Likewise, sublingual daily dose should be stopped 3 days before COVID-19 vaccine administration and restarted 7 days after [18].

2) Medium risk (Yellow zone)

This zone includes the following clinical pictures.

- History of anaphylactic reactions to foods, insects, latex.

The following definition of anaphylaxis was considered in these cases: “Anaphylaxis is a serious systemic hypersensitivity reaction that is usually rapid in onset and may cause death. Severe anaphylaxis is characterized by potentially life-threatening compromise in breathing and/or the circulation, and may occur without typical skin features or cardiovascular shock being present” [19].

Action: If the cause of anaphylaxis is confirmed, COVID-19 vaccination can be performed. Most international documents suggest [7, 9–11, 20] to proceed with vaccination as normal (in the green zone). However, considering that some patients who developed allergic reactions after BNT162b2 vaccine have a previous history of food anaphylaxis [21–23] we suggest performing the vaccine in vaccination centers equipped for anaphylaxis management [6, 24].

- Idiopathic anaphylaxis and exercise-induced anaphylaxis.

Action: Proceed with the vaccination (in centers and facilities equipped for anaphylaxis management or in the hospital setting, according to teleconsulting or diagnostic workup [14, 16].

- Mastocytosis.

COVID-19 vaccination is generally recommended in patients with mastocytosis. Safety measures, including pharmacological pre-medication and post-vaccination observation, should be considered in all patients with mastocytosis, depending on the individual risk and general conditions of every single case [16, 25].

Action: In most cases, proceed with routine vaccination in an outpatient setting with emergency awareness and emergency medication available (24). Pre-medication with sedating or non-sedating H1 antihistamine and supervision for 60 minutes after vaccination should be considered.

For the high-risk population (previous anaphylaxis, also to a vaccine, known or suspected allergy to excipients, systemic mastocytosis): see red zone.

- Uncontrolled asthma.

According to GINA document [26], asthma in children is not controlled if the child (or parents) answers “yes” at least to 3 of these questions: i) Presence of daytime asthma symptoms more than twice/week?; ii) Is there any night waking due to asthma?; iii) Use of Short-Acting Beta-Agonists (SABA) reliever for symptoms more than twice/week?; iv) Is there any activity limitation due to asthma?

Action: Try to reach the best possible asthma control and then proceed to vaccination. If asthma is severe or only partially controlled, proceed with vaccination in a hospital setting with an observation of at least 60 minutes [16, 27]. COVID-19 vaccine should be administered 2–7 days after biologic administration in asthmatic patients treated with biologics [18].

- Large local reaction to previous COVID-19 vaccination.

Action: some documents [11, 14, 28] include this reaction in the green zone. However, according to other consensus (8), we suggest to perform teleconsulting and eventually specific risk assessment in some cases of immediate reaction, in order to exclude a possible allergy to PEG or another excipient. The general indication is to perform vaccination in an outpatient setting with emergency awareness and emergency medication available. Pre-medication with H1 antihistamine should be considered.

- Immediate allergic reactions to drugs or vaccines.

Action: specific risk assessment concerning a possible PEG (or another excipient) allergy is required [14, 16, 29]. If skin tests result negative, vaccination should be performed in a hospital setting with an observation of at least 60 minutes. If skin tests result positive, refer to the red zone.

Generally, allergy assessment or teleconsulting are indicated in all above cases, if requested by pediatricians or vaccination centers. According to the allergy assessment or teleconsulting, vaccination should be performed in settings where symptoms of anaphylaxis can be recognized as early as possible and promptly treated with epinephrine and further emergency treatment or in hospital settings where it is possible to continue monitoring/treating of the patient in case of need [13, 16, 17, 27]. The allergy assessment or teleconsulting aims to make a certain diagnosis and give specific indications: modify ther-
apy in case of uncontrolled or partially controlled asthma, or pharmacological pre-medication.

3) High risk (Red zone)

This zone includes patients with the following:

- Positive skin tests to excipients
- Previous allergic reaction to the specific vaccine
- Previous severe allergic reaction to a vaccine component or drugs, including PEG or trometamol

Action: perform allergy risk assessment; consider that sensitivity and specificity for a skin test to excipients is unknown, and the diagnostic utility of PEG and polysorbate allergy testing is uncertain [5]. According to skin test results, the patient may be considered ineligible for a further vaccination or eligible for another vaccination containing another excipient negative to the skin test. Vaccination in fractionated doses could be considered in selected cases [14]. In all these cases, vaccination must be carried out under strict control in a hospital setting where emergency medical services for resuscitation are available [9, 16, 28].

Final remarks

Even if the risk of anaphylaxis to COVID-19 mRNA vaccines, particularly to BNT162b2 vaccine, in children aged 5–11 years seems very low [4, 29], nevertheless a prudent approach still appears advisable as anaphylaxis is often unpredictable [13]. In case of previous systemic reaction to COVID-19 vaccines or drugs, including excipients contained in COVID-19 vaccines, an allergic evaluation is necessary, even if the evidence on the diagnostic utility of skin test for PEG or other excipients is still uncertain [5]. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions [14]. All vaccine centers should follow national and international guidelines and have staff trained in recognizing and managing anaphylaxis [10, 13].

COVID-19 vaccination in children with primary or acquired immunodeficiencies or history of multisystem inflammatory syndrome - children (MIS-C)/pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS)

Primary and acquired immunodeficiency syndromes encompass several heterogeneous conditions ranging from mild oligosymptomatic defects to severe diseases, with the phenotype of overwhelming opportunistic infections, autoinflammation, or immune dysregulation. Therefore, it is challenging to provide a “one-fits-all” recommendation for all children and adolescents affected by immunodeficiency syndromes. However, in general, no absolute contraindication exists to vaccination with approved mRNA or viral vector inactivated vaccines in individuals affected by primary or secondary immune defects [30, 31].

A consistent number of patients affected by inborn errors of immunity (IEI), including antibody deficiency syndromes under immunoglobulin replacement therapy, may mount an effective immune response against SARS-CoV-2 vaccines. Indeed, the type and strength of immune response could be very different accordingly to the type of IEI and the main immune compartment involved (i.e., the presence of a preserved adaptive B-cell and/or T-cell function) but also the patient's therapy regimen under which the COVID-19 vaccine is administrated [31–34]. At the time of these recommendations, very little information exist about the efficacy of the anti-SARS-CoV-2 vaccine in patients affected by IEI, and consulting with a pediatric immunologist in most cases is advisable.

Very few data also exist about the risk/benefit ratio of anti-SARS-CoV-2 vaccination in children 5 to 11-years-old with previous MIS-C/PIMS-TS, although in theory even in these patients the benefits of COVID-19 vaccination outweigh the potential risks of triggering a relapse in the disease [34, 35]. However, in patients with MIS-C/PIMS-TS who have been treated with high-dose intravenous immunoglobulins (IVIG), it is suggested to start the vaccine schedule 6 months after IVIG administration, as well as full recovery and cardiac function normalization [34]. If untreated with IVIG, starting the COVID-19 vaccination may be considered 3 months after full recovery. Moreover, to the best of current knowledge, the next dose administration should be withheld in children who developed MIS-C/PIMS-TS after the COVID-19 vaccination. However, according to the available information, it is conceivable that these recommendations could change in the future.

Conclusion

A teleconsulting visit with the referral pediatric immunologist is advisable in patients affected by IEI, acquired immunodeficiencies, and previous MIS-C/PIMS-TS.

Abbreviations

PEG: polyethylene glycol; SIAIP: Società Italiana di Allergologia ed. Immunologia Pediatrica; SIAIC: Società Italiana Allergologia Immunologia Clinica; AAITO: Associazione Allergologi Italiani Territoriali Ospedalieri; MIS-C: Multisystem Inflammatory Syndrome - Children; PIMS-TS: Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2; IEI: inborn errors of immunity; IVIG: intravenous immunoglobulins.
Acknowledgements
The authors want to thank the Italian Society of Pediatric Allergy and Immunology for its support in relation to this work.

Authors’ contributions
EN and MT conceptualized, designed the work, acquired, analyzed the data, drafted the initial manuscript and reviewed the manuscript. FC designed the work and drafted the initial manuscript. GLM analyzed the data and reviewed the manuscript. CC, MC, FC, RC, EC, CCR MM, MD, AL, SM, AM, GR, GP analyzed the data and helped to draft the manuscript and reviewed the manuscript. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The publication fee was financed by the Italian Society of Pediatric Allergy and Immunology. However, no significant funding source could have influenced the outcomes of this work.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests to disclose in relation to this paper.

Author details
1Allergy Unit, Department of Pediatrics, Meyer Children’s University Hospital, Florence, Italy. 2Allergy Center, Istituto Gianna Gaslini, Genoa, Italy. 3Pediatric Clinic, Department of Medicine and Surgery, University of Parma, Via Gramsci, 14 Parma, Italy. 4Operative Unit of Pediatrics, S. Camillo-Forlanini Hospital, Rome, Italy. 5Pediatric Unit, Azienda Ospedaliero-Universitaria Policlinico-Giovanni XXIII, Bari, Italy. 6Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. 7Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. 8Paediatric Infectious Diseases Unit, Department of Health Sciences, Anna Meyer Children’s University Hospital, University of Florence, Florence, Italy. 9ATS Pavia, Pavia, Italy. 10Department of Woman and Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy. 11Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy. 12Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy. 13Pediatrician at the University of Pavia, Pavia, Italy. 14Alma Mater Studiorum, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 15Pediatrician and Allergist, Rome, Italy.

Received: 24 February 2022 Accepted: 4 May 2022

Published online: 16 May 2022

References
1. European medicines agency: https://www.ema.europa.eu/en/medicines/human/EPAR/cominarty. Accessed 2 Dec 2022.
2. Ministero della Salute: https://www.trovanorme.salute.gov.it/norme/ renderNormianPdf?annno=2021&codLeg=84353&parte=1%20&serie=null. Accessed 12 Feb 2022.
3. Burgstede SD, Geersing TH, Tempels-Pavlica Z. Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines. Allergy. 2021;76:1941–2.
4. Hause AM, Baggs J, Marquez P, Myers TR, Gee J, Su JR, et al. COVID-19 vaccine safety in children aged 5–11 years - United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1755–60.
5. Greenhawt M, Abrams EM, Shaker M, Chu DK, Khani D, Akin C, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9:3546–67.
6. Tuyts S, Van Der Brempt X, Faber M, Gadisseur R, Desfouliau B, Schrijvers R, et al. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI). Acta Clin Belg. 2021;1:1–6. https://doi.org/10.1080/17843286.2021.1900944. Epub ahead of print.
7. Vander Leek-Th, Chan ES, Connors L, Derflavi B, Ellis AK, Upton JEM, et al. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. 2021;17:29.
8. Kim MA, Lee YW, Kim SR, Kim JH, Min TK, Park HS, et al. COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI (Urticaria/an.goedema/anaphylaxis working group. Allergy Asthma Immunol Res. 2021;13:526–44.
9. Worm M, Bauer A, Wedi B, Treudler P, Pfleutzer W, Brockow K, et al. Practical recommendations for the allergological risk assessment of the COVID-19 vaccination - a harmonized statement of allergy centers in Germany: Allergologe. 2021;5:72–6.
10. Turner PJ, Ansotegui IJ, Campbell DC, Cardona V, Ebisawa M, El-Gamal Y, et al. On behalf of the WAO anaphylaxis committee. COVID-19 vaccine-associated anaphylaxis: a statement of the world allergy organization anaphylaxis committee. World Allergy Organ J. 2021;14:100517.
11. Tanno KS, Berard F, Beaudoin F, Didier A, Demoly P. On behalf of the Montpellier WHO collaborating center and French allergy society (SFA). SARS-CoV-2 vaccination and anaphylaxis: recommendations of the French allergy community and the Montpellier World Health Organization collaborating center. Vaccines. 2021;9:560.
12. Murphy KR, Patel NC, Ed D, Hudelson M, Kodoth S, Gailen D, et al. Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines. Ann Allergy Asthma Immunol. 2021;126:319–20.
13. Sokolowska M, Ewegeger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management, and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021;76:1629–39.
14. Barbaud A, Garvey LH, Arcolaci A, Brockow K, Moni F, Mayorga C, et al. Allergies and COVID-19 vaccines: an ENDA/EAACI position paper: Allergy. 2022. https://doi.org/10.1111/1398-9995.15241. Online ahead of print.
15. Tosca M, Miraglia Del Giudice M, Cardinale F, Licari A, Caffarelli C, Cravidi C, Calvani M, Martelli A, Chiappini E, Manti A, Novembre E, Marseglia GL. Gestione della vaccinazione per COVID-19 in soggetti di età 12–18 anni con asma, asma anafilattico e immunodeficienze SIAIP Novembre 2021. https://www.siaip.it/siti/sezioni/3/area2/Medicina%20Documenti.
16. AAITO/SAACI Linee di indirizzo per la dirigenza per la gestione da parte degli allergologi dei pazienti a rischio di reazioni allergiche ai vaccini per COVID-19 Versione 15/02/21. https://www.siaip.it/siti/sezioni/3/area2/Medicina% 20Documenti.
17. Gollo G, Miel R, Ros E, Filia A. Guida alle controindicazioni ai vaccini, quinta edizione - Febbraio 2018 Ministero della Sanità. https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano& id=2759.
18. Julot M, Torres MJ, Palomares O, Aikis CA, Ewegeger T, Untersmayr E, et al. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations. Allergy. 2022. https://doi.org/10.1111/1398-9995.15252. Online ahead of print.
19. Turner PJ, Worm M, Ansotegui IJ, El-Gamal Y, Rivas MF, Fineman S, et al. Time to revisit the definition and clinical criteria for anaphylaxis? World Allergy Organ J. 2019;12:100066.
20. ASCIA, Allergy, Immunodeficiency, autoimmunity and COVID-19 vaccination position statement updated 20 2021. https://www.ascia.org/wp- papers/ascia-hp-position-statement-covid-19-vaccination.
21. CDC. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:46–51.
22. Hashimoto T, Ozaki A, Bhandari D, Sawano T, Sah R, Tanimoto T. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data. J Travel Med. 2021;28:taa090.

23. Liotti L, Bianchi A, Bottau R, Caimmi S, Crisafulli G, Franceschini F, et al. COVID-19 vaccines in children with cow’s milk and food allergies. Nutrients. 2021;13:2637.

24. Alhumaid S, Mutair AA, Al Alawi Z, Rabaaan AA, Tirupathi R, Alomari MA, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17:109.

25. Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Niedoszytko B, et al. COVID-19 vaccination in Mastocytosis: recommendations of the European competence network on Mastocytosis (ECNM) and American initiative in mast cell diseases (AIM). J Allergy Clin Immunol Pract. 2021;9:2139–44.

26. GINA. https://ginasthma.org/ginareports/.

27. AIFA. https://www.aifa.gov.it/documents/20142/1297852/demande_risposte_vaccini_COVID.pdf.

28. Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9:1423–37.

29. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390–13.

30. Milota T, Strizova Z, Smetanova J, Sediva A. An immunologist’s perspective on anti-COVID-19 vaccines. Curr Opin Allergy Clin Immunol. 2021;21:545–52.

31. Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021;148:739–49.

32. Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticaro M, et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Allergy Clin Immunol. 2021;148:1192–7.

33. Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno C, Medri C, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850.

34. Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate V, Lang H, Lazanski CA, et al. Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency. J Clin Immunol. 2021;41:1146–53.

35. Paediatric Rheumatology European Society. PRES update regarding COVID-19 vaccination in children with rheumatic diseases. https://www.pres.eu/clinical_affairs/guidelines.html.

36. Poussaint TY, La Rovere KL, Newyrgwe JW, Chou J, Nigrovic LE, Novak T, et al. Multisystem inflammatory-like syndrome in a child following COVID-19 mRNA vaccination. Vaccine (Basels). 2022;10:43.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.